Mixed trend on the daily chart: above its 50-day average · SuperTrend up since Sep 8 · inside the Ichimoku cloud · RSI 50 · MACD below its signal
None of the 29 investors followed here reported a position in 6998.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 6998.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.22 per share. | 13K | $2.92K |
| Sep 13, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.22 per share. | 2.41M | $522.73K |
| Sep 10, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.22 per share. | 200K | $43.34K |
| Sep 9, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.22 per share. | 200K | $44.48K |
| Sep 8, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.22 per share. | 200K | $43.06K |
| Sep 7, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.22 per share. | 116.5K | $25.05K |
| Sep 6, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.22 per share. | 150K | $32.31K |
| Sep 3, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.21 per share. | 311K | $65.84K |
| Sep 2, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.21 per share. | 150K | $31.50K |
| Sep 1, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.21 per share. | 150K | $30.91K |
| Aug 31, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.21 per share. | 150K | $31.53K |
| Aug 30, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.20 per share. | 185K | $37.20K |
| Jun 24, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.23 per share. | 100K | $22.66K |
| Jun 23, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.23 per share. | 100K | $22.89K |
| Jun 22, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.23 per share. | 200K | $45.86K |
| Jun 21, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.23 per share. | 200K | $46.40K |
| Jun 17, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.24 per share. | 823K | $197.19K |
| Jun 16, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.23 per share. | 200K | $46.06K |
| Jun 15, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.23 per share. | 334.5K | $75.33K |
| Jun 14, 2026 | Ni (Xin)Chief Executive Officer | Acquisition at price 0.23 per share. | 500.5K | $114.31K |
No analyst coverage for this instrument.
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial. It also provides Vancocin for multidrug-resistant gram-positive bacteria; Ceclor for mild to moderate community-acquired bacterial infections in children; Yirui Ping for nebulized inhalation therapy; Vascepa for cardiovascular risk reduction; Mulpleta for reducing bleeding risk; Jing Zhu Da for breast cancer treatment; Recormon for CRA indication; and three siRNA candidates for chronic disease treatment, as well as entinostat and lerociclib hydrochloride tablets. In addition, the company is involved in marketing, commercialization, and trading of pharmaceutical products; research and development of respiratory products; and consultancy and promotion services. Its products are used in oncology, autoimmune, cardiovascular, respiratory, and anti-infective therapeutic areas. Edding Genor Group Holdings Limited was founded in 2001 and is headquartered in Zhuhai, China.
No recent headlines.